Aptinyx Inc (NASDAQ:APTX) shares hit a new 52-week low during trading on Wednesday . The stock traded as low as $5.02 and last traded at $5.08, with a volume of 4123304 shares traded. The stock had previously closed at $17.83.
Separately, Cantor Fitzgerald reiterated a “buy” rating and issued a $40.00 target price on shares of Aptinyx in a report on Wednesday. Five analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $34.25.
Aptinyx (NASDAQ:APTX) last posted its quarterly earnings results on Tuesday, November 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.58. The company had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $1.10 million. As a group, analysts anticipate that Aptinyx Inc will post -2.33 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2019/01/16/aptinyx-aptx-hits-new-1-year-low-at-5-02.html.
Aptinyx Company Profile (NASDAQ:APTX)
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Further Reading: Do back-end load funds outperform no-load funds?
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.